FIELD: neurological diseases.
SUBSTANCE: composition contains therapeutically effective amount of anticonvulsant agent dissolved or dispersed in aqueous carrier containing 10-80 vol % aliphatic alcohol, 10-80 vol % ethylene glycol, and 0.1-5 vol % bile acid salt or lecithin. Indicated carrier ensures increased access of anticonvulsant agent (such as benzodiazepin, in particular diazepam, clonazepam, phoenitoin, mephoenitoin, ethotoin, phenobarbital, carbamazepin, ethosuccinamide, valproic acid, gabapentine, trimethadion, lamotrigin) into blood and rapid pharmacological response when using nasal administration.
EFFECT: accelerated anticonvulsant effect.
11 cl, 9 dwg, 10 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR THE ELIMINATION OF CONVULSIVE SYNDROME BASED ON NIKETHAMIDE AND MEDICINAL PRODUCTS OF THE BENZODIAZEPINE GROUP | 2022 |
|
RU2801050C1 |
| TRANSNASAL MICROEMULSIONS CONTAINING DIAZEPAM | 2004 |
|
RU2354354C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD FOR PULMONARY ADMINISTRATION THEREOF | 2010 |
|
RU2445119C2 |
| APPLICATION OF 1-AR(ALK)YLIMIDAZOLINE-2- ONS IN TREATING STATE OF FEAR AND ANXIETY | 1998 |
|
RU2203055C2 |
| PHARMACEUTICAL COMPOSITION WITH ANTICONVULSANT ACTIVITY FOR PARENTERAL INTRODUCTION | 2011 |
|
RU2463052C1 |
| COMPOSITIONS CONTAINING TRIPTANE COMPOUNDS | 2010 |
|
RU2710372C2 |
| INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE | 2012 |
|
RU2657441C1 |
| COMPOSITIONS CONTAINING TRIPTANE COMPOUNDS | 2019 |
|
RU2762725C2 |
| LIQUID DRUG RESERVOIRS | 2005 |
|
RU2390331C2 |
| INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE | 2012 |
|
RU2587051C2 |
